Hungry biotechs make better partners for Big Pharma

All that moaning and groaning you've been hearing about how hard it is to find venture backing for biotechs these days is evidently cause for considerable enthusiasm in pharma circles. The Wall Street Journal's Goran Mijuk says the funding crisis has helped Big Pharma companies like Roche do more deals with smaller upfronts. And that's allowed Roche to bring in hot new drugs like Zelboraf (Plexxikon) and vismodegib, another skin cancer treatment partnered with Curis. "We are doing around 50 to 60 partnership deals a year now, compared to around 30 deals per year before the crisis [of 2008]," Dan Zabrowski, head of Roche's drug partnership unit, tells the Journal. "Today, we start deals earlier with less upfront payments and share the risk with our partners." Report

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.